Hormonal
Females are protected from inflammation-induced muscle wasting (cancer cachexia) compared to males, likely due to estrogen's ability to blunt inflammatory responses and lower basal ubiquitin-proteasome activity.
For women undergoing cancer treatment involving cachexia, hormonal status (specifically estrogen) may offer some natural protection against severe muscle wasting compared to men. This doesn't mean muscle loss won't happen, but the mechanism is different. Maintaining hormonal balance and managing inflammation are key, as estrogen helps blunt the inflammatory signals that drive this specific type of muscle loss.
In general, females appear to be more susceptible to disuse induced muscle wasting, yet protected from inflammation induced (such as cancer cachexia) muscle wasting compared to males.
Why this rating
Supported by multiple citations regarding estrogen's anti-inflammatory effects and sex-specific differences in catabolic pathway activity.
Source
Muscle metabolism and atrophy: let’s talk about sex
Megan E. Rosa‐Caldwell et al. · Biology of Sex Differences · 2019
DOI 10.1186/s13293-019-0257-3
More from this paper
- Females exhibit greater susceptibility to disuse-induced muscle atrophy compared to males, evidenced by faster onset of muscle loss and greater percent loss of oxidative (Type I) muscle mass during conditions like hindlimb unloading or ICU bed rest.Good
- Females have greater basal autophagy activity but lower basal ubiquitin-proteasome activity compared to males, leading to different catabolic responses during muscle stress.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →